Journal of Clinical Oncology
Articles in this Issue
Access to fertility preservation services among commercially insured adults with early-onset colorectal cancer.
38 Background: Despite the increasing number of adults diagnosed with, treated for, and surviving colorectal cancer (CRC)...
Comparative analysis of readmission drivers in right- versus left-sided colorectal cancer: Insights from a national database.
49 Background: Colorectal cancer is the third leading cause of cancer death in men and the fourth in women. The American C...
Concordance of programmed death-ligand 1 (PD-L1) status in primary esophageal squamous cell carcinoma (ESCC) and matched visceral metastases.
435 Background: PD-L1 expression is a predictive biomarker for response to first-line immunochemotherapy (anti-PD-1 therap...
Source matters: Performance of guideline-anchored RAG versus broad evidence LLMs in GI oncology.
805 Background: Adherence to NCCN guidelines in GI oncology is inconsistent, and large language models (LLMs) can stray fr...
The Liver Cancer and Frailty in Elderly (LIFE) study: Understanding longitudinal functional status in patients with advanced hepatocellular carcinoma (HCC) and aspartate aminotransferase-to-platelet ratio index (APRI).
527 Background: Hepatocellular carcinoma (HCC) is a significant contributor to cancer related mortality and morbidity in o...
Impact of response to gemcitabine-based neoadjuvant therapy on the outcomes of gemcitabine plus nab-paclitaxel after recurrence in pancreatic cancer.
675 Background: Gemcitabine (GEM)-based neoadjuvant chemoradiotherapy is administered to facilitate curative resection in...
Artificial intelligence–enhanced biomarker analysis of WNT, TGF-β, and PI3K pathway alterations in FOLFOX-treated early-onset colorectal cancer in high-risk populations.
236 Background: Early-onset colorectal cancer (EOCRC; <50 years) is rising rapidly, with the steepest increases among H...
Early symptom patterns among young Medicaid-insured individuals with colorectal cancer: A population-based analysis.
24 Background: Survey and anecdotal data from patients with early-onset colorectal cancer (EOCRC) suggest that they are mo...
Geographic variations in gastrointestinal cancer mortality: A comprehensive analysis of U.S. regional disparities.
819 Background: Gastrointestinal (GI) cancers remain a significant public health concern in the United States, with notabl...
Impact of robot-assisted surgery on postoperative sexual function in younger male rectal cancer patients.
63 Background: The purpose of this study was to investigate postoperative sexual dysfunction in male rectal cancer patient...
The efficacy and safety of third-line regorafenib versus fruquintinib in the treatment of metastatic colorectal cancer: A meta-analysis.
171 Background: Colorectal cancer (CRC) is the second most common cause of cancer-related mortality after lung cancer. Thi...
National trends and predictors of 90-day all-cause readmission in hepatocellular carcinoma: A real-world outcomes study using the Nationwide Readmissions Database.
491 Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of ca...
Influence of multiomics on tumor microenvironment remodeling in locally advanced rectal cancer following neoadjuvant chemoradiotherapy plus immunotherapy.
230 Background: Immune checkpoint inhibitors (ICIs) have limited efficacy in microsatellite-stable (MSS) or mismatch repai...
A phase Ib trial on the safety and feasibility of low-dose radiotherapy combined with immunochemotherapy for colorectal cancer with liver-limited metastasis (TRIUNITE-04).
TPS272 Background: Liver metastasis is the leading cause of death in patients with CRC. Despite significant progress in th...
Effect of peripheral ANGPTL3 on the efficacy of anti-PD1 therapy for advanced gastric cancer.
425 Background: Anti-PD1/PDL1 therapy has attracted great attention in cancer therapy in recent years, whereas only a smal...
Activity of DEM301, a novel anti-DEM-TXX antibody-drug conjugate for the treatment of gastrointestinal tumors.
159 Background: DEM301 is a novel antibody-drug conjugate (ADC) consisting of a humanized, afucosylated monoclonal antibod...
Real-world molecular profile and treatment patterns in advanced gastroesophageal adenocarcinoma: A Brazilian multicenter cohort.
313 Background: Advanced (A) gastroesophageal adenocarcinoma (GA) prognosis remains poor, with limited data on molecular p...
Prognostic value of the modified Glasgow Prognostic Score in patients with metastatic pancreatic cancer: An exploratory analysis of JCOG1611.
760 Background: The modified Glasgow Prognostic Score (mGPS), which combines serum levels of C-reactive protein and albumi...
BMI at diagnosis and pre-diagnosis weight loss as predictors of stage and survival in hepatocellular carcinoma.
522 Background: Body mass index (BMI) is a recognized risk factor for hepatocellular carcinoma (HCC), but its relationship...
Curative therapy after atezolizumab and bevacizumab treatment for unresectable hepatocellular carcinoma: A multinational retrospective study.
TPS607 Background: The combination of atezolizumab and bevacizumab (Atezo-Bev) has transformed the treatment landscape for...
Conversion surgery for stage IV gastric cancer: Real-world insights with a focus on elderly patients (OGSG2301).
311 Background: Recent advances in systemic chemotherapies, especially molecular targeted drugs and immune checkpoint inhi...
Phase 2 ILUSTRO trial of 1L zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2+ locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.
LBA284 Background: The anti-CLDN18.2 antibody zolbetuximab plus chemotherapy has shown efficacy in patients with CLDN18.2+...
Stability of immune microenvironment changes associated with progression risk in Barrett’s esophagus.
450 Background: Barrett’s esophagus (BE) is the principal risk factor for esophageal adenocarcinoma (EAC). Since only a sm...
Conditional recurrence-free survival after curative resection of esophageal cancer: Integrated analysis of individual patient data from 11 randomized controlled trials.
345 Background: Most recurrences after curative surgery for esophageal cancer occur within two years. However, conventiona...
BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
13 Background: Leucovorin/5-FU in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are common chemotherapies...